Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
Our patients are at the center of everything we do Keeping you healthy and feeling your best is our top priority. We start by putting you first. Our doctors take the time to listen and get to know you. Understanding your health care goals helps them coordinate your care to make sure you get the services you need.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 employees in 77 countries, and markets its products in more than 165 countries.